Ignite Creation Date:
2025-12-24 @ 2:50 PM
Ignite Modification Date:
2026-02-02 @ 3:04 AM
Study NCT ID:
NCT05188859
Status:
RECRUITING
Last Update Posted:
2025-05-31
First Post:
2021-12-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-09-01
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09
Completion Date Type:
ESTIMATED
First Submit Date:
2021-12-27
First Submit QC Date:
None
Study First Post Date:
2022-01-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-27
Last Update Post Date:
2025-05-31
Last Update Post Date Type:
ACTUAL